This week EyesOn Pharma is highlighting some recent business deals that are helping BioPharma firms execute their Strategic Plans. See more on Roche's manufacturing improvements, Earendil Labs' deal to further their antibody production, and Novo's cardiometabolic product line-extension deal.

With blockbuster sales of Caplyta, Johnson & Johnson’s $14.6 billion investment in Intra-Cellular Therapies continues to pay off.

BioPharma dealmaking is still going strong this summer. We're highlighting a few companies that caught our EyesOn team attention. Check out details on the Roche + Hanmi, Leo Pharma + Tanabe, and the SK BioPharma + Biohaven deals. By paying $190 million up front for a clinical-stage UCN2 (urocortin-2) analogue from South Korea’s Hanmi Pharm, Roche has advanced its obesity approach into unprecedented territory. Eli Lilly investigated the mechanism in a heart failure medicatio

We've had EyesOn some of the latest News Makers in the BioPharma Sector. Today we're covering two that caught our interest, Moderna's cancer vaccine data + the new choice for the FDA Commisioner.

We still have EyesOn Clinical Asset updates. This week we cover GSK's FDA approval for Jideytro, Royalty's ATTR deal, plus the Sanofi and Roche portfolio adjustments that include discontinuation of some assets.

We've been keeping EyesOn Strategic moves in the BioPharma space. Today we look at BioNTech's new CEO, Pfizer's continuing restructuring moves to remain competitive, and the reactions to a potential BMS + AZN merger.